ReNeuron Group plc Notification of Interim Results (0361P)
14 November 2016 - 7:00AM
UK Regulatory
TIDMRENE
RNS Number : 0361P
ReNeuron Group plc
14 November 2016
14 November 2016 AIM: RENE
ReNeuron Group plc
("ReNeuron" or "the Company")
Notification of Interim Results
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, intends to announce its
interim results for the six months ended 30 September 2016 on
Monday 5 December 2016.
The Company also expects to announce initial three month
follow-up data from the PISCES II clinical trial of its CTX cell
therapy candidate for stroke disability on the same day.
A meeting for analysts will be held at 9.00am on the morning of
5 December 2016 at the offices of Buchanan, 107 Cheapside, London
EC2V 6DN.
For a webcast of the analyst presentation, please log on to the
following web address approximately 10 minutes before 9.00am on the
day of the results:
http://vm.buchanan.uk.com/2016/reneuron051216/registration.htm
A recording of the presentation will be made available on
ReNeuron's and Buchanan's websites, www.reneuron.com and
www.buchanan.uk.com
Enquiries:
ReNeuron +44 (0)20 3819 8400
Olav Hellebø , Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan +44 (0) 20 7466 5000
Mark Court, Sophie Cowles, Stephanie Watson
Stifel Nicolaus Europe Limited +44 (0) 20 7710 7600
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Broker)
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development
company. Based in the UK, its primary objective is the development
of novel cell-based therapies targeting areas of significant unmet
or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop
cell-based therapies for significant disease conditions where the
cells can be readily administered "off-the-shelf" to any eligible
patient without the need for additional immunosuppressive drug
treatments. The Company has therapeutic candidates in clinical
development for motor disability as a result of stroke, for
critical limb ischaemia and for the blindness-causing disease,
retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential new nanomedicine targeting cancer and as a
potential delivery system for gene therapy treatments.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. Further information on ReNeuron and its products can
be found at www.reneuron.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOREANFDFAKKFFF
(END) Dow Jones Newswires
November 14, 2016 02:00 ET (07:00 GMT)